Legal & Disputes
Schall, Brown & Schwartz Investigates Syndax Pharmaceuticals Over Disclosures After MAXPIRe Trial Failure
By News Desk ·
Key takeaways
- Schall, Brown & Schwartz LLP is investigating Syndax Pharmaceuticals for potential securities law violations tied to disclosures around its Phase 2 MAXPIRe trial.
- Syndax announced on October 12, 2026, that the Phase 2 MAXPIRe trial of axatilimab failed to achieve its primary endpoint.
- Syndax shares fell more than 15.7% the day after the trial failure was disclosed.
Schall, Brown & Schwartz LLP is investigating Syndax Pharmaceuticals, Inc. for violations of the securities laws, the firm said in a Business Wire announcement. The investigation focuses on whether the company issued false or misleading statements or failed to disclose information pertinent to investors, according to the firm.
What the SBS Investigation Covers
The investigation follows Syndax's October 12, 2026 announcement that its Phase 2 MAXPIRe trial evaluating axatilimab failed to achieve its primary endpoint. Shares of Syndax fell by more than 15.7% on the next day, according to the firm. Schall, Brown & Schwartz said it is investigating claims on behalf of investors of Syndax, which trades on the Nasdaq under the symbol SNDX. The firm said shareholders who suffered a loss can contact Brian Schall or David Schwartz to discuss their rights free of charge. "Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor," the firm said. The firm describes itself as a national shareholder rights litigation firm specializing in securities class action lawsuits.
Syndax's Recent Funding and Approvals
Syndax Pharmaceuticals is a commercial-stage oncology biopharmaceutical company that develops and markets targeted therapies for acute leukemias and chronic graft-versus-host disease, anchored by Revuforj and Niktimvo, according to akta.pro company records. The same records show Syndax priced $250 million of 2.25% convertible senior notes due 2031 in a private placement in June 2026, with J. Wood Capital Advisors as sole placement agent. The FDA expanded approval of Revuforj (revumenib) in October 2025 to include adult and pediatric patients with relapsed or refractory NPM1-mutated acute myeloid leukemia, materially expanding the drug's addressable population beyond the initial KMT2Ar indication. Syndax appointed Nick Botwood, M.B.B.S. as Head of Research & Development and Chief Medical Officer in May 2025, replacing Neil Gallagher.
Earlier Events Leading to the Investigation
Syndax ended development of a lung disease treatment after a mid-stage trial failed to meet its main goal of reducing annual lung function decline, The future of trading reported on October 12, 2026. Syndax Pharmaceuticals shares fell 17.2% after its Phase 2 trial of axatilimab missed its primary endpoint, Benzinga reported on October 13, 2026. At the H.C. Wainwright conference on September 15, 2026, Syndax outlined its business, with Revuforj and Niktimvo each annualizing over $200 million in revenue, Investing.com reported.
What Comes Next for Syndax
Schall, Brown & Schwartz said shareholders who suffered a loss can participate in the investigation and contact the firm to discuss their rights free of charge.